Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supreme Pre-emption: Legislators, Journals, Former FDA Heads Unite vs. Wyeth

Executive Summary

The plaintiff bar and the pharmaceutical industry have rallied their allies as they prepare for a hearing before the U.S. Supreme Court that could change the outcome of product liability litigation

You may also be interested in...

Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case

This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation

FDA Finalizes Labeling Rule As Pre-emption Battle At Supreme Court Looms

January’s proposed rule remains mostly unchanged, but the definition of “newly acquired information” is slightly broader now.

Supreme Court Reaches Tie Vote in FDA Preemption Case

Court lets lower court ruling against Warner-Lambert stand but does not answer question regarding federal preemption in product liability.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts